Christopher Ryan Sullivan Sells 7,980 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Ryan Sullivan sold 7,980 shares of the stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $17.15, for a total value of $136,857.00. Following the sale, the chief financial officer owned 17,338 shares in the company, valued at $297,346.70. The trade was a 31.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Ryan Sullivan also recently made the following trade(s):

• On Wednesday, April 1st, Christopher Ryan Sullivan sold 7,979 shares of Avalo Therapeutics stock. The shares were sold at an average price of $16.77, for a total value of $133,807.83.

Avalo Therapeutics Price Performance

Shares of AVTX opened at $17.76 on Friday. The company has a market cap of $404.75 million, a P/E ratio of -3.10 and a beta of 0.93. The stock has a fifty day moving average price of $15.54 and a 200 day moving average price of $16.01. Avalo Therapeutics, Inc. has a 12 month low of $3.39 and a 12 month high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($1.54) by $1.17. The company had revenue of $0.06 million during the quarter, compared to analyst estimates of ($0.21) million. As a group, research analysts anticipate that Avalo Therapeutics, Inc. will post -19.07 earnings per share for the current year.

Institutional Investors Weigh In On Avalo Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BIT Capital GmbH acquired a new stake in Avalo Therapeutics in the third quarter worth approximately $25,000. PFS Partners LLC raised its stake in shares of Avalo Therapeutics by 100.0% in the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after buying an additional 1,000 shares in the last quarter. Quadrature Capital Ltd bought a new stake in shares of Avalo Therapeutics in the 2nd quarter worth $55,000. Dimensional Fund Advisors LP acquired a new stake in shares of Avalo Therapeutics in the third quarter valued at $143,000. Finally, Boothbay Fund Management LLC bought a new position in Avalo Therapeutics during the second quarter valued at about $56,000. Institutional investors own 87.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on AVTX. BTIG Research reiterated a “buy” rating and issued a $40.00 price objective on shares of Avalo Therapeutics in a research report on Tuesday, March 24th. Mizuho upgraded shares of Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Wall Street Zen upgraded shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. Finally, HC Wainwright boosted their price objective on Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Avalo Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $42.25.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.